Advanced Magnetics To Weigh European Trial Data For Combidex “Approvable” Response
This article was originally published in The Pink Sheet Daily
Executive Summary
European development partner Guerbet has submitted a marketing application to the EMEA seeking a narrower indication for the molecular imaging agent.
You may also be interested in...
Advanced Magnetics' Combidex "Approvable" Letter Requests More Efficacy Data
The decision follows the Oncologic Drugs Advisory Committee vote that current data do not support approval of the imaging agent for the proposed indication. FDA suggested that the data be "limited to a well-defined population of specific cancer types," the company says.
Celgene To Submit Revlimid Phase III Special Protocol Assessment For CLL To FDA Shortly
Firm notes strong uptake of the product in 2006, as well as more than $400 million in Thalomid sales for the year during earnings call.
AstraZeneca Continues Pipeline Expansion Via Two Licensing Deals Totaling $800 Million
Agreements expand the firm’s position in the COPD space, while also entering obesity, diabetes and metabolic syndrome space.